{"id":8887,"date":"2026-04-02T16:45:00","date_gmt":"2026-04-02T09:45:00","guid":{"rendered":"https:\/\/www.globenewswire.com\/news-release\/2026\/04\/02\/3267174\/0\/en\/Arch-Biopartners-Closes-Non-Brokered-Private-Placement.html3267174"},"modified":"2026-04-02T16:53:00","modified_gmt":"2026-04-02T09:53:00","slug":"arch-biopartners-closes-non-brokered-private-placement","status":"publish","type":"post","link":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/","title":{"rendered":"Arch Biopartners Closes Non-Brokered Private Placement"},"content":{"rendered":"\n<p align=\"justify\">TORONTO, April 02, 2026 (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=egHL4L2KESEvE_ZVWf2REZtXGn3Wrww9WW2YUifvQXaS3TtLXoJCtNX06qVE_pyT5bebRPqd0SwAh6bzO6O5r9mn8puJGA9ciuJnbVAZs3A=\" rel=\"nofollow\" target=\"_blank\" title=\"Arch Biopartners Inc\">Arch Biopartners Inc<\/a>. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d).<\/p>\n<p align=\"justify\">The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding grants. The Offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including final approval from the TSX Venture Exchange.<\/p>\n<p align=\"justify\">The Offering involved the issuance of 81,667 Common Shares to an officer of the Company and therefore a \u201crelated party\u201d (as such term is defined under Multilateral Instrument 61-101 \u2013&nbsp;<em>Protection of Minority Security Holders in Special Transactions&nbsp;<\/em>(&#8220;<strong>MI 61-101<\/strong>&#8220;)) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(a) of MI 61-101, as the fair market value of the Common Shares distributed and the consideration received from the related party in the Private Placement does not exceed 25% of the Company&#8217;s market capitalization.<\/p>\n<p align=\"justify\">All Common Shares issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date of April 2, 2026. There were no finders\u2019 fees to be paid in connection with the Offering.<\/p>\n<p align=\"justify\">There is no material fact or material change about the Company that has not been generally disclosed.<\/p>\n<p align=\"justify\"><strong>About Arch Biopartners<\/strong><\/p>\n<p align=\"justify\">Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.<\/p>\n<p align=\"justify\">Arch\u2019s development pipeline includes:<\/p>\n<ul type=\"disc\">\n<li><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J6C2BGFqayHvUzFSMFzWtat4FxMWho7VtoErB9QUGgk-vBvlXkK3DfnxOi6G0OigIcIR6y9x7CUk44uRK0sJfGugxG274mGwXXK3tCt6dyFmy0L5MMFckqbSVt7Rw5FxgmgmUP-QrNXqiU7MCOuy6g==\" rel=\"nofollow\" target=\"_blank\" title><strong>LSALT peptide:<\/strong><\/a> in a Phase II trial targeting cardiac surgery-associated AKI.<\/li>\n<li><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J6C2BGFqayHvUzFSMFzWtUWU04t3a7rSpsgVK13tVWOJ5MnJAkyH2ELyqlNbXV2BukvRU0XnuZBDLSL4DMyWUzuiHpWljOxvTcI3AqXX1pytBdZAvUP4iLqCHnJJ9NL0dnwjRwsNjUI4gc57BPBSbA==\" rel=\"nofollow\" target=\"_blank\" title><strong>Cilastatin:<\/strong><\/a> a repurposed drug in a Phase II trial targeting toxin-induced AKI.<\/li>\n<li><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J6C2BGFqayHvUzFSMFzWtacB4ZkFRnX9Y5EQlNcC57_ZA9wRfmvJihdj7Me6FPFxCvkKI7Pqzc5kDCKtgtTfhrsfliGtRFBvfE7gHEtnSusuvY0fvVOgsGf_0Wn1dW2P5rUez166sfEL3LxnWq8jLw==\" rel=\"nofollow\" target=\"_blank\" title><strong>CKD Platform:<\/strong><\/a> next-generation therapeutics targeting chronic kidney disease.<\/li>\n<\/ul>\n<p>These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide<sup>1<\/sup>. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.<\/p>\n<p align=\"justify\">For more details about the Company\u2019s science and ongoing clinical trials, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XtXEm0QFfMQg8Bh63VVO6zoOHFuE_00PfUYZ5R69ulJcbZ-P8Uqa6kor1J-_7yaS5OgKFaJ6F1BCGEEoIgZ5dQ-1JVo0w6S06Ujd70kE5t4WaGeGxumen9QTS9pZdRtep0EXC_tVMhnnOPX1sA9QHw==\" rel=\"nofollow\" target=\"_blank\" title=\"www.archbiopartners.com\/our-science\">www.archbiopartners.com\/our-science<\/a><\/p>\n<p align=\"justify\">Follow Arch on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xc3ueJHtkEm2qPZ2P_f3t3Qh2fSXV7Yzc1-I7pne10SBGpoICfIYf1RxqxNlNc_VnROsNBt1npvSofgmzlYGsbB7uvS2iPV6lLHP8L7H5cDXNxW06N1qfZrxULHlCILh\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gQee6zKBa_pmr6VotlbqzqC6xg0HV5aldH8KD3WQ8G8vJqE7RcmpPCmWKRmvAFcRwyKJxU1uENN4veLu_2xeIUb69j0CvRGOji9OewWKj2w=\" rel=\"nofollow\" target=\"_blank\" title=\"Bluesky\">Bluesky<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QN66jwm7OeRzRtU8--WiPpQcWdSXO0o8-yQ-EaLar-Z8_e7GxAUDhOHU_1DtCV36JzIfItX_Pgxwyj287l_oxYZJ00qKK0XIV6Y0o-G9vuA=\" rel=\"nofollow\" target=\"_blank\" title=\"X (formerly Twitter)\">X (formerly Twitter)<\/a> for scientific insights and industry news.<\/p>\n<p>The Company has 67,933,289 common shares outstanding.<\/p>\n<p><strong>For more information, please contact:<\/strong><\/p>\n<div class=\"pcrstb-wrap\"><table>\n<tr>\n<td>Aaron Benson<br \/>Director of Communications<br \/>Arch Biopartners, Inc. <br \/>647-428-7031<\/td>\n<td>&nbsp;<\/td>\n<\/tr>\n<\/table><\/div>\n<p>Send a message or subscribe for trial updates and company news at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XtXEm0QFfMQg8Bh63VVO6zoOHFuE_00PfUYZ5R69ulJw-IC-WNeXm-fWkPok4HRvnUgFik6flp84CKHhiudY_by-VIuXkR6R09veMPDDU2amfwdQV4oJ1KoE3oTHVHqjOkLMeL8bGBfBkvXDTfDMZw==\" rel=\"nofollow\" target=\"_blank\" title=\"www.archbiopartners.com\/contact-us\">www.archbiopartners.com\/contact-us<\/a><\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company\u2019s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management\u2019s current expectations and beliefs, including certain factors and assumptions, as described in the Company\u2019s most recent annual audited financial statements and related management discussion and analysis under the heading \u201cBusiness Risks and Uncertainties\u201d. As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words \u201cbelieve\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201ccontinue\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cexpect\u201d, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company\u2019s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators\u2019 System for Electronic Document Analysis and Retrieval (\u201cSEDAR\u201d) website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C7RZOmR-AaJSvl3dpnqQG8r3voeEUAOCu7wKtVGGiN71qoJY60c96tytYERJtnnhGIbhCP-hGEMmJIouATBn5qCpYVSbrEtfWO2Re3ltD-g=\" rel=\"nofollow\" target=\"_blank\" title=\"www.sedarplus.ca\">www.sedarplus.ca<\/a>.<\/p>\n<p align=\"justify\"><strong>References: <\/strong><\/p>\n<ol>\n<li>Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. <em>The Lancet<\/em>, 2025;406(10518), 2461 &#8211; 2482. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fqCqBWTS1GnRQUKlSvc3PTNdLGnN24EAkEDOinXRfXtqHffShBJkVzTjgbqSUNAuQypMgZrljjG5GwvP0K-x1FeCowu3LyRLei-6Wu63kyWP1cuGA_GD1HsCG_nysN2KrVLwdaFzVcKIfOBSAHdeo0bo0yOhG83v8EYEB8KuuLKt_HIMCxE5LmEqMyUX_a6de6fNS3ANY4blZ6NkcFE3prgrBmSnk99wW3jUNaDAj8X0wBVFW9GGewk72fyZ0O1M\" rel=\"nofollow\" target=\"_blank\" title>https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(25)01853-7\/fulltext<\/a><\/li>\n<\/ol>\n<p align=\"center\"><em>The scientific and medical content of this release has been reviewed and approved by the Company\u2019s Chief Science Officer.<\/em><\/p>\n<p align=\"center\"><em>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/em><\/p>\n<p><img decoding=\"async\" alt src=\"https:\/\/ml.globenewswire.com\/media\/YjA0NmQ3YTEtMTkxNy00YTQyLWJmNDctMjY3MDk2NGZjMTJhLTExMDUyMDgtMjAyNi0wNC0wMi1lbg==\/tiny\/Arch-Biopartners.png\" referrerpolicy=\"no-referrer-when-downgrade\">  <\/p>\n","protected":false},"excerpt":{"rendered":"<p> TORONTO, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding&#8230;<\/p>\n","protected":false},"author":1,"featured_media":8888,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[75,1406],"tags":[],"class_list":["post-8887","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-globenewswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arch Biopartners Closes Non-Brokered Private Placement<\/title>\n<meta name=\"description\" content=\"TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arch Biopartners Closes Non-Brokered Private Placement\" \/>\n<meta property=\"og:description\" content=\"TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/\" \/>\n<meta property=\"og:site_name\" content=\"Crypto Insider\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/yourcryptoinsider\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T09:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T09:53:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/YjA0NmQ3YTEtMTkxNy00YTQyLWJmNDctMjY3MDk2NGZjMTJhLTExMDUyMDgtMjAyNi0wNC0wMi1lbg==\/tiny\/Arch-Biopartners.png\" \/>\n<meta name=\"author\" content=\"Crypto Insider\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi\" \/>\n\t<meta name=\"twitter:data1\" content=\"Crypto Insider\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/\"},\"author\":{\"name\":\"Crypto Insider\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\"},\"headline\":\"Arch Biopartners Closes Non-Brokered Private Placement\",\"datePublished\":\"2026-04-02T09:45:00+00:00\",\"dateModified\":\"2026-04-02T09:53:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/\"},\"wordCount\":860,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/arch-biopartners-closes-non-brokered-private-placement.gif\",\"articleSection\":[\"Business\",\"GlobeNewswire\"],\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/\",\"name\":\"Arch Biopartners Closes Non-Brokered Private Placement - Crypto Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/arch-biopartners-closes-non-brokered-private-placement.gif\",\"datePublished\":\"2026-04-02T09:45:00+00:00\",\"dateModified\":\"2026-04-02T09:53:00+00:00\",\"description\":\"Crypto and Blockchain News\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/arch-biopartners-closes-non-brokered-private-placement.gif\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/arch-biopartners-closes-non-brokered-private-placement.gif\",\"width\":1,\"height\":1},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/arch-biopartners-closes-non-brokered-private-placement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Business\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/business\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Arch Biopartners Closes Non-Brokered Private Placement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"name\":\"Crypto Insider\",\"description\":\"Crypto and Blockchain News\",\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\",\"name\":\"Crypto Insider\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"width\":2048,\"height\":2048,\"caption\":\"Crypto Insider\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/yourcryptoinsider\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/vietnaminsider\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\",\"name\":\"Crypto Insider\",\"description\":\"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain\",\"sameAs\":[\"https:\\\/\\\/cryptoinsider.asia\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arch Biopartners Closes Non-Brokered Private Placement","description":"TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding...","og_locale":"vi_VN","og_type":"article","og_title":"Arch Biopartners Closes Non-Brokered Private Placement","og_description":"TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (\u201cArch\u201d or the \u201cCompany\u201d) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the \u201cCommon Shares\u201d) for gross proceeds of $600,000 CAD (the \u201cOffering\u201d). The proceeds of the Offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the Company\u2019s human trial funding...","og_url":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/","og_site_name":"Crypto Insider","article_publisher":"https:\/\/www.facebook.com\/yourcryptoinsider","article_published_time":"2026-04-02T09:45:00+00:00","article_modified_time":"2026-04-02T09:53:00+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/YjA0NmQ3YTEtMTkxNy00YTQyLWJmNDctMjY3MDk2NGZjMTJhLTExMDUyMDgtMjAyNi0wNC0wMi1lbg==\/tiny\/Arch-Biopartners.png","type":"","width":"","height":""}],"author":"Crypto Insider","twitter_card":"summary_large_image","twitter_misc":{"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi":"Crypto Insider","\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc":"4 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#article","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/"},"author":{"name":"Crypto Insider","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6"},"headline":"Arch Biopartners Closes Non-Brokered Private Placement","datePublished":"2026-04-02T09:45:00+00:00","dateModified":"2026-04-02T09:53:00+00:00","mainEntityOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/"},"wordCount":860,"commentCount":0,"publisher":{"@id":"https:\/\/cryptoinsider.asia\/#organization"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/04\/arch-biopartners-closes-non-brokered-private-placement.gif","articleSection":["Business","GlobeNewswire"],"inLanguage":"vi","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/","url":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/","name":"Arch Biopartners Closes Non-Brokered Private Placement - Crypto Insider","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#primaryimage"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/04\/arch-biopartners-closes-non-brokered-private-placement.gif","datePublished":"2026-04-02T09:45:00+00:00","dateModified":"2026-04-02T09:53:00+00:00","description":"Crypto and Blockchain News","breadcrumb":{"@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/"]}]},{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#primaryimage","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/04\/arch-biopartners-closes-non-brokered-private-placement.gif","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/04\/arch-biopartners-closes-non-brokered-private-placement.gif","width":1,"height":1},{"@type":"BreadcrumbList","@id":"https:\/\/cryptoinsider.asia\/vi\/arch-biopartners-closes-non-brokered-private-placement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cryptoinsider.asia\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/cryptoinsider.asia\/category\/news\/"},{"@type":"ListItem","position":3,"name":"Business","item":"https:\/\/cryptoinsider.asia\/category\/business\/"},{"@type":"ListItem","position":4,"name":"Arch Biopartners Closes Non-Brokered Private Placement"}]},{"@type":"WebSite","@id":"https:\/\/cryptoinsider.asia\/vi\/#website","url":"https:\/\/cryptoinsider.asia\/vi\/","name":"Crypto Insider","description":"Crypto and Blockchain News","publisher":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cryptoinsider.asia\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Organization","@id":"https:\/\/cryptoinsider.asia\/vi\/#organization","name":"Crypto Insider","url":"https:\/\/cryptoinsider.asia\/vi\/","logo":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","width":2048,"height":2048,"caption":"Crypto Insider"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/yourcryptoinsider","https:\/\/www.linkedin.com\/company\/vietnaminsider"]},{"@type":"Person","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6","name":"Crypto Insider","description":"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain","sameAs":["https:\/\/cryptoinsider.asia"]}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/04\/arch-biopartners-closes-non-brokered-private-placement.gif","jetpack-related-posts":[],"jetpack_likes_enabled":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/8887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/comments?post=8887"}],"version-history":[{"count":0,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/8887\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media\/8888"}],"wp:attachment":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media?parent=8887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/categories?post=8887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/tags?post=8887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}